Paul Rennie Buys 5,181,688 Shares of Paradigm Biopharmaceuticals Limited (ASX:PAR) Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie bought 5,181,688 shares of the stock in a transaction dated Tuesday, February 11th. The shares were acquired at an average price of A$0.50 ($0.32) per share, with a total value of A$2,590,844.00 ($1,639,774.68).

Paradigm Biopharmaceuticals Stock Performance

The company has a quick ratio of 5.93, a current ratio of 7.22 and a debt-to-equity ratio of 1.01. The company has a market cap of $196.66 million, a PE ratio of -2.47 and a beta of 0.94.

Paradigm Biopharmaceuticals Company Profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.